^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RCSD1 (RCSD Domain Containing 1)

    i
    Other names: RCSD1, RCSD Domain Containing 1, RCSD Domain-Containing Protein 1, Protein Kinase Substrate CapZIP, CapZ-Interacting Protein, CAPZIP, Protein Kinase Substrate MK2S4, CapZ Interacting Protein, MK2S4
    2ms
    Bacterial ubiquitin ligase engineered for small molecule and protein target identification. (PubMed, EMBO J)
    We validate the method with known small molecule-protein interactions and use it to identify CaMKII as an off-target interactor of the breast cancer drug ribociclib...Structural and biochemical studies indicate that RavB allosterically binds CapZ and decaps actin, thus functionally mimicking eukaryotic CapZ interacting proteins. Collectively, our results establish SidBait as a reliable tool for identifying targets of small molecules and proteins.
    Journal
    |
    RCSD1 (RCSD Domain Containing 1)
    |
    Kisqali (ribociclib)
    11ms
    Bacterial ubiquitin ligase engineered for small molecule and protein target identification. (PubMed, bioRxiv)
    We validate the method with known small molecule-protein interactions and use it to identify CaMKII as an off-target interactor of the breast cancer drug ribociclib...Structural and biochemical studies indicate that RavB allosterically binds CapZ and decaps actin, thus functionally mimicking eukaryotic CapZ interacting proteins. Collectively, our results establish SidBait as a reliable tool for identifying targets of small molecules and proteins.
    Journal
    |
    RCSD1 (RCSD Domain Containing 1)
    |
    Kisqali (ribociclib)
    2years
    Proteome microarray identifies autoantibody biomarkers for diagnosis of hepatitis B-related hepatocellular carcinoma. (PubMed, Clin Chim Acta)
    The APEX2, RCSD1, and TP53 biomarker panels could be used for the diagnosis of HBV-associated HCC, providing a scientific basis for clinical practice.
    Journal
    |
    TP53 (Tumor protein P53) • AFP (Alpha-fetoprotein) • RCSD1 (RCSD Domain Containing 1)
    over2years
    Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients. (PubMed, Int J Cancer)
    The GWA gene-based analysis yielded for RCSD1 the most significant association with differential OS in mCRC (P = 6.6 × 10 ). With further investigation into its biological mechanisms, this finding could potentially be used to individualize first-line treatment and improve clinical outcomes.
    Journal
    |
    RCSD1 (RCSD Domain Containing 1)
    |
    oxaliplatin
    almost3years
    DECIPHER STRUCTURAL ABERRATIONS OF THE PAX5 GENE AND THEIR CORRELATION WITH DIAGNOSTIC CLASSIFICATION AND TREATMENT OUTCOME IN B CELL LYMPHOBLASTIC LEUKEMIA (EHA 2023)
    PAX5 structural aberrations are common and important genetic events in B-ALL with various forms, including in- frame gene fusions, 3' deletion ( PAX5::ZCCHC7 ), and focal exon deletions. OGM combined with RNA-seq helps to decipher pathological PAX5 structural abnormalities. PAX5 structural abnormalities mostly occur in BCR::ABL1 - positive and BCR::ABL1 -like patients and are often associated with IK10.
    Clinical • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCL2 (B-cell CLL/lymphoma 2) • RUNX1 (RUNX Family Transcription Factor 1) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • PAX5 (Paired Box 5) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • NUP214 (Nucleoporin 214) • PBX1 (PBX Homeobox 1) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase) • EBF1 (EBF Transcription Factor 1) • RCSD1 (RCSD Domain Containing 1)
    |
    PAX5 fusion • PAX5 deletion
    almost3years
    Fusion landscape in acute leukemias: A submerged world of not routinely characterized transcripts (AACR 2023)
    we identified pivotal transcripts in all ALs and an unexpected high rate of secondary Fs in adult ALs subgroups (52.4%) that are not characterized with conventional diagnostic methods. The use of an NGS approach and a powerful pipeline permit us to detect Fs useful for a better classification, prognostic identification (e.g. TBL1XR1-MECOM) and in some cases to find targetable Fs (e.g.
    IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCL2 (B-cell CLL/lymphoma 2) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • MECOM (MDS1 And EVI1 Complex Locus) • NUP214 (Nucleoporin 214) • CSF1R (Colony stimulating factor 1 receptor) • RCSD1 (RCSD Domain Containing 1) • TBL1XR1 (TBL1X Receptor 1) • ZNF384 (Zinc Finger Protein 384)
    over3years
    Pan-cancer analysis reveals the relationship between RCSD1 immune infiltration and clinical prognosis in human tumors. (PubMed, Front Immunol)
    In human cancer, RCSD1 plays an important role in the tumor microenvironment (TME) and is significantly associated with the expression of immune infiltrating cells (TIL) in lung cancer. As a prognostic biomarker of generalized cancer, RCSD1 is associated with immune infiltration.
    Journal • Pan tumor
    |
    RCSD1 (RCSD Domain Containing 1)
    almost5years
    [VIRTUAL] IDENTIFICATION AND MOLECULAR CHARACTERIZATION OF BCR-ABL1-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA IN INDIAN PATIENTS (EHA 2021)
    Conclusion We have reported the incidence and devised a logistic regression based simple, efficient, cost-effective classifier for the rapid detection of BCR-ABL1 like ALL cases for the first time; which is likely to be suitable for developing countries. It is very important to detect BCR-ABL1-like ALL cases, so as to provide these patients the benefits of treatment stratification (including desirable TKI therapy) and prognostication.
    Clinical
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • JAK2 (Janus kinase 2) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • PAX5 (Paired Box 5) • FOXP1 (Forkhead Box P1) • RCSD1 (RCSD Domain Containing 1)
    |
    BCR-ABL1 fusion • IKZF1 deletion • ABL1 deletion